The impact of preclinical irreproducibility on drug development

The development of novel therapeutics depends and builds upon the validity and reproducibility of previously published data and findings. Yet irreproducibility is pervasive in preclinical life science research and can be traced to cumulative errors or flaws in several areas, including reference mate...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacology and therapeutics Vol. 97; no. 1; p. 16
Main Authors Freedman, L P, Gibson, M C
Format Journal Article
LanguageEnglish
Published United States 01.01.2015
Subjects
Data Collection - methods
Data Collection - standards
Drug Design
Drug Evaluation, Preclinical - methods
Humans
Reproducibility of Results
Research Design - standards
Online AccessGet more information

Cover

More Information
Summary:The development of novel therapeutics depends and builds upon the validity and reproducibility of previously published data and findings. Yet irreproducibility is pervasive in preclinical life science research and can be traced to cumulative errors or flaws in several areas, including reference materials, study design, laboratory protocols, and data collection and analysis. The expanded development and use of consensus-based standards and well-documented best practices is needed to both enhance reproducibility and drive therapeutic innovations.
ISSN:1532-6535
DOI:10.1002/cpt.9